BLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
NEMLUVIO (nemolizumab-ilto) by Galderma is interleukin-31 receptor alpha antagonists [moa]. First approved in 2024.
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEMLUVIO (nemolizumab-ilto) is a monoclonal antibody that antagonizes the interleukin-31 receptor alpha, a key driver of pruritus and inflammation. It is approved for treating moderate-to-severe atopic dermatitis and addresses the unmet need for patients with severe itching not controlled by existing therapies. The drug represents a novel mechanism targeting the IL-31 pathway, distinguishing it from JAK inhibitors and other current standard-of-care agents.
Growth
Early-stage launch phase with limited competitive pressure (30%) suggests expanding commercial infrastructure and headcount growth in sales, medical affairs, and field teams.
Mechanism of Action
Interleukin-31 Receptor alpha Antagonists
Pharmacologic Class:
Interleukin-31 Receptor alpha Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NEMLUVIO positions you at the forefront of a newly launched mechanism in a high-value atopic dermatitis market; growth-stage dynamics mean expanding teams and career advancement opportunities in commercial and medical functions. The differentiated IL-31 pathway and moderate competitive intensity create a favorable environment for brand building, market share capture, and clinical strategy innovation over the next 3–5 years.
Brand Manager
Worked on NEMLUVIO at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.